Idiopathic Pulmonary Fibrosis Ipf clinical trials

Explore recruiting idiopathic pulmonary fibrosis ipf clinical trials.

Recruiting idiopathic pulmonary fibrosis ipf studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Idiopathic Pulmonary Fibrosis Ipf trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability and Efficacy of Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) in Patients with Idiopathic Pulmonary Fibrosis (RENEW)

Germany, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF)

Croatia, Ireland, Netherlands, Spain, France, Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)

Greece, France, Netherlands, Italy, Spain, Czechia +5 more

Phase II and Phase III (Integrated) EU CTIS Study details

A Randomized, Double-Blind, Placebo-Controlled, Parallel, 4-Arm Dose Ranging Study of the Safety and Efficacy of Nalbuphine Extended-Release Tablets (NAL ER) for the Treatment of Cough in Idiopathic Pulmonary Fibrosis (IPF)

Germany, Netherlands, Italy, Spain, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized Double-Blind Study to Evaluate the Efficacy and Safety of CAL101 in Patients with Idiopathic Pulmonary Fibrosis

Spain, Norway, Netherlands, Denmark, Romania, France +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A participant - and investigator-blinded, randomized, placebo-controlled, multicenter, platform study to investigate efficacy, safety, and tolerability of various single treatments in patients with idiopathic pulmonary fibrosis

Germany, Czechia, Netherlands, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

Idiopathic Pulmonary Fibrosis Ipf trials by city

Idiopathic Pulmonary Fibrosis Ipf in Toronto Idiopathic Pulmonary Fibrosis Ipf in Vancouver Idiopathic Pulmonary Fibrosis Ipf in Montreal Idiopathic Pulmonary Fibrosis Ipf in Calgary Idiopathic Pulmonary Fibrosis Ipf in Edmonton Idiopathic Pulmonary Fibrosis Ipf in Ottawa Idiopathic Pulmonary Fibrosis Ipf in Winnipeg Idiopathic Pulmonary Fibrosis Ipf in Quebec City Idiopathic Pulmonary Fibrosis Ipf in Hamilton Idiopathic Pulmonary Fibrosis Ipf in Kitchener Idiopathic Pulmonary Fibrosis Ipf in London Idiopathic Pulmonary Fibrosis Ipf in Halifax Idiopathic Pulmonary Fibrosis Ipf in New York Idiopathic Pulmonary Fibrosis Ipf in Los Angeles Idiopathic Pulmonary Fibrosis Ipf in Chicago Idiopathic Pulmonary Fibrosis Ipf in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease